Ophthalmic composition


Ontology type: sgo:Patent     


Patent Info

DATE

2012-07-03T00:00

AUTHORS

Jun Inoue , Tapan Shah

ABSTRACT

The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol. More... »

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2447", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Jun Inoue", 
        "type": "Person"
      }, 
      {
        "name": "Tapan Shah", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.2147/opth.s3182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001959803"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jconrel.2004.09.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008806172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.drudis.2007.10.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011725778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jconrel.2004.10.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018813124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1295/polymj.17.117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029771046", 
          "https://doi.org/10.1295/polymj.17.117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030917319", 
          "https://doi.org/10.1038/sj.gt.3302579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030917319", 
          "https://doi.org/10.1038/sj.gt.3302579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/cr900068q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034165950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/cr900068q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034165950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2003.11.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047378732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1039/c39900001010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048231433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1520-6017(200007)89:7<946::aid-jps12>3.3.co;2-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054250396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bc0342128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055153607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bc0342128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055153607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bm801310d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055224179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bm801310d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055224179"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-07-03T00:00", 
    "description": "

The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.

", "id": "sg:patent.US-8211450-B2", "keywords": [ "composition", "invention", "hyperbranched polymer", "carbonic anhydrase inhibitor", "wherein", "aqueous solubility", "permeation", "active agent", "surfactant", "Polysorbates", "cellulose", "beta-blockers", "timolol", "propranolol" ], "name": "Ophthalmic composition", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.492934.1", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-8211450-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:09", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_00362.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-8211450-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-8211450-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-8211450-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-8211450-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

78 TRIPLES      15 PREDICATES      40 URIs      22 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-8211450-B2 schema:about anzsrc-for:2447
2 schema:author N4a10b39605c04e8f940dcd81504aad9d
3 schema:citation sg:pub.10.1038/sj.gt.3302579
4 sg:pub.10.1295/polymj.17.117
5 https://doi.org/10.1002/1520-6017(200007)89:7<946::aid-jps12>3.3.co;2-u
6 https://doi.org/10.1016/j.drudis.2007.10.021
7 https://doi.org/10.1016/j.ijpharm.2003.11.035
8 https://doi.org/10.1016/j.jconrel.2004.09.015
9 https://doi.org/10.1016/j.jconrel.2004.10.004
10 https://doi.org/10.1021/bc0342128
11 https://doi.org/10.1021/bm801310d
12 https://doi.org/10.1021/cr900068q
13 https://doi.org/10.1039/c39900001010
14 https://doi.org/10.2147/opth.s3182
15 schema:datePublished 2012-07-03T00:00
16 schema:description <p id="p-0001" num="0000">The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.</p>
17 schema:keywords Polysorbates
18 active agent
19 aqueous solubility
20 beta-blockers
21 carbonic anhydrase inhibitor
22 cellulose
23 composition
24 hyperbranched polymer
25 invention
26 permeation
27 propranolol
28 surfactant
29 timolol
30 wherein
31 schema:name Ophthalmic composition
32 schema:recipient https://www.grid.ac/institutes/grid.492934.1
33 schema:sameAs https://app.dimensions.ai/details/patent/US-8211450-B2
34 schema:sdDatePublished 2019-04-18T10:09
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher N958487c6891f46629aab9d6dafdd2a07
37 sgo:license sg:explorer/license/
38 sgo:sdDataset patents
39 rdf:type sgo:Patent
40 N4a10b39605c04e8f940dcd81504aad9d rdf:first N8b0c9695bad04e45832d30222de5736e
41 rdf:rest Nf85bd0021c5b49b2894ec62d0447ac75
42 N8b0c9695bad04e45832d30222de5736e schema:name Jun Inoue
43 rdf:type schema:Person
44 N958487c6891f46629aab9d6dafdd2a07 schema:name Springer Nature - SN SciGraph project
45 rdf:type schema:Organization
46 Nbc4be30fdc694fb19e207cf0cd5a3aa3 schema:name Tapan Shah
47 rdf:type schema:Person
48 Nf85bd0021c5b49b2894ec62d0447ac75 rdf:first Nbc4be30fdc694fb19e207cf0cd5a3aa3
49 rdf:rest rdf:nil
50 anzsrc-for:2447 schema:inDefinedTermSet anzsrc-for:
51 rdf:type schema:DefinedTerm
52 sg:pub.10.1038/sj.gt.3302579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030917319
53 https://doi.org/10.1038/sj.gt.3302579
54 rdf:type schema:CreativeWork
55 sg:pub.10.1295/polymj.17.117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029771046
56 https://doi.org/10.1295/polymj.17.117
57 rdf:type schema:CreativeWork
58 https://doi.org/10.1002/1520-6017(200007)89:7<946::aid-jps12>3.3.co;2-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1054250396
59 rdf:type schema:CreativeWork
60 https://doi.org/10.1016/j.drudis.2007.10.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011725778
61 rdf:type schema:CreativeWork
62 https://doi.org/10.1016/j.ijpharm.2003.11.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047378732
63 rdf:type schema:CreativeWork
64 https://doi.org/10.1016/j.jconrel.2004.09.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008806172
65 rdf:type schema:CreativeWork
66 https://doi.org/10.1016/j.jconrel.2004.10.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018813124
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1021/bc0342128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055153607
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1021/bm801310d schema:sameAs https://app.dimensions.ai/details/publication/pub.1055224179
71 rdf:type schema:CreativeWork
72 https://doi.org/10.1021/cr900068q schema:sameAs https://app.dimensions.ai/details/publication/pub.1034165950
73 rdf:type schema:CreativeWork
74 https://doi.org/10.1039/c39900001010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048231433
75 rdf:type schema:CreativeWork
76 https://doi.org/10.2147/opth.s3182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001959803
77 rdf:type schema:CreativeWork
78 https://www.grid.ac/institutes/grid.492934.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...